申请人:Jubian Vrej
公开号:US20070213376A1
公开(公告)日:2007-09-13
This invention is directed to halogenated sulfonamide derivatives which are ligands at the NPY Y5 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by admixing a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of treating a subject suffering from depression which comprises administering to the subject an amount of a compound of the subject invention. This invention also provides a method of treating a subject suffering from anxiety which comprises administering to the subject an amount of a compound of the subject invention. This invention also provides a method of treating a subject suffering from obesity which comprises administering to the subject an amount of a compound of the subject invention. Furthermore, the present invention is directed to use of a compound of the invention for the manufacture of a medicament for treating a subject suffering from depression, anxiety or obesity.
本发明涉及卤代磺酰胺衍生物,其是NPY Y5受体的配体。该发明提供了一种制药组合物,包括本发明化合物的治疗有效量和药学可接受的载体。本发明还提供了一种通过混合本发明化合物的治疗有效量和药学可接受的载体制备的制药组合物。本发明还提供了一种制备制药组合物的方法,包括将本发明化合物的治疗有效量和药学可接受的载体混合。此外,本发明还提供了一种治疗患有抑郁症的受试者的方法,包括向受试者施用本发明化合物的量。本发明还提供了一种治疗患有焦虑症的受试者的方法,包括向受试者施用本发明化合物的量。本发明还提供了一种治疗患有肥胖症的受试者的方法,包括向受试者施用本发明化合物的量。此外,本发明还涉及使用本发明化合物制造治疗患有抑郁症、焦虑症或肥胖症的受试者的药物。